BIO 2026 | San Diego

BLPN’s capital readiness and investor relations program for a select roster of Life Sciences Operators preparing to compete at the highest level through BLPN Member-guided resources. View the slideshow below to learn more, or click to view in a PDF format.

BIO Week 2026 Roster Money Ball Feedback Form
Next Cohort : April - June 2026

Vetted | BLPN Community

Coached | BLPN Dealmakers

Funded | BLPN Investors

Podcasts Featuring Money Ball

Load video:

The Healthy Enterprise Podcast: James Lovgren, Aspiro Therapeutics

In this conversation, James Lovgren shares his insights on the funding process for biotech startups, emphasizing the importance of team expertise, the art of pitching, and the need to balance scientific detail with storytelling.

Watch Episode
Load video:

The Healthy Enterprise Podcast: Robert Boyce, Plakous Therapeutics

In this episode, Rob Boyce, CEO of Plakous Therapeutics, discusses the company's mission to develop regenerative medicine solutions for necrotizing enterocolitis (NEC), a devastating disease affecting premature infants.

Watch Episide
Load video:

The Healthy Enterprise Podcast: Doug Cohen, IR Medtek

In this episode of The Healthy Enterprise, host Heath Fletcher interviews Doug Cohen, the Co-Founder and CEO of IR Medtek, about his journey in developing a groundbreaking technology for cancer detection.

Watch Episode
Load video:

The Healthy Enterprise Podcast: Chandi Bandara, Precision Quantomics

In this episode of The Healthy Enterprise, host Heath Fletcher speaks with Chandi Bandara, CEO of Precision Quantomics, about the challenges and innovations in drug development. They discuss the inefficiencies in the pharmaceutical industry, the importance of effective pitching to investors, and the insights gained from the Money Ball program.

Watch Episode
Load video:

Selling Science Podcast: Linda Templeman, Persista Bio LSX

Recorded live at LSX, Linda Templeman of Persista Bio sits down with Selling Science Podcast to discuss the evolving biomarker landscape and how data-driven diagnostics are reshaping oncology investment and partnering opportunities.

Watch Episode

“One of the greatest strengths of this program was the people. The coaches never held back in their input, and that honesty and candor were a major plus. Beyond that, so many other members also stepped in to support and guide me throughout—reminding me that this truly is a community built on collective success.”

— Chandi Bandara, Money Ball BIO 2025 Player, CEO, Precision Quantomics

“Very valuable and helpful.  It provided some real world feedback and some great connections for us moving forward.  Coaches are awesome and do a nice job of guidance and discussion as we refined our message.”

— Doug Cohen, Money Ball BIO 2025 Player, CEO, IR Medtek

“The respect, collaboration and support that the BLPN team engenders - even when many balls are in the air and adjustments are being made - that's what makes this an incredible experience and worth the time and effort. So a big, heart-felt THANK YOU!”

— Michael Hill, Money Ball BIO 2025 Head Coach, Co-Founder of Science Innovations, LLC

“From my perspective as Head Coach, the real value of the Money Ball program is that it takes brilliant founders and gives them the structure, discipline, and confidence to step into the investor arena. Founders often start with powerful science but without a clear commercial identity or investor-ready story. Money Ball closes that gap. It equips CEOs with the tools—licensing strategy, valuation benchmarks, pitch discipline, and clear milestones—that transform an early-stage idea into a fundable company. . . .”

— Stella Vnook, Head Coach for BIO 2025, Founder of Agile Consulting Group